the aid library

LIST OPTIONS

Filter

1200

Sort by:

Direction:

Download (386)

View PDF (689)

Integrating the prevention, treatment and care of mental health conditions and other noncommunicable diseases within health systems

World Health Organization WHO, Regional Office for Europe (2019) C_WHO

Mental health conditions affect one in 10 people at any one time and account for a large proportion of non-fatal disease burden. There is a high degree of comorbidity between mental health conditions such as depression and other noncommunicable diseases (NCDs), including cardiovascular disease, diab... more

Download (146)

View PDF (883)

Cognitive profiles of Post-traumatic Stress Disorder and depression in children and adolescents

Barrera-Valenciaa, M., Calderón-Delgado, L., Trejos-Castillo, E. & O’Boyle, M. International Journal of Clinical and Health Psychology (2017) CC

Several diagnostic criteria of Post-traumatic Stress Disorder (PTSD) are remarkably similar to symptoms reported by individuals with depression, particularly as they manifest as cognitive processing deficits in children. Because of this overlap in profile and the high rate of comorbidity of PTSD and... more

Download (35)

View PDF (29)

COPD Wheel - International Primary Care - Respiratory Group

International Primary Care Respiratory Group (IPCRG) International Primary Care Respiratory Group (IPCRG) (2024) CC2

The document is a visual guide created by the IPCRG for managing COPD, focusing on self-management, treatment options (such as inhaler use, pulmonary rehabilitation, and medications), and addressing comorbidities. It highlights the importance of personalized care plans, patient education, risk reduc... more

Download (28)

View PDF (42)

Severe and Difficult Asthma: Diagnosis and Management—Challenges for a Low‐Resource Environment

Bush, A. Springer Link (2021) CC2

Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ... more

Download (176)

View PDF (165)

Risk factors of Cholera mortality

Global Task Force On Cholera Control (GTFCC) (2022) CC

To better adapt current case management practices and address excess mortality in otherwise treatable cases will require better knowledge of the demographic characteristics of the patients and comorbidities which can make severe dehydration harder to tolerate physiologically. With this in mind, a ... more

Download (309)

View PDF (220)

A primary health care approach to obesity prevention and management in children and adolescents: policy brief

World Health Organisation (WHO) (2023) C_WHO

Obesity in all age groups, including children and adolescents, is a public health challenge across all settings. Obesity is now classified as a complex multifactorial chronic disease and not just a risk factor for other noncommunicable diseases and comorbidities. Recognizing the significance of prim... more

Download (85)

View PDF (144)

Guidelines for Dialysis of COVID – 19 patients

Government of India Ministry of Health & Family Welfare (2020) C2

COVID-19, a disease caused by a novel corona virus (SARS CoV-2), is currently a pandemic, which produces high morbidity in the elderly and in patients with associated comorbidities. Chronic kidney disease stage-5 (CKD-5) patients on dialysis [maintenance hemodialysis (MHD)or continuous ambulatory pe... more

Download (29)

View PDF (33)

Management of Type 2 Diabetes Mellitus

Richardson, C.R.; Borgeson, J. R.; Harrison, V.; et al. National Library of Medicine (2021) CC2

The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio... more

Download (24)

View PDF (26)

Under- and over-diagnosis of COPD: a global perspective

Ho T., Cusack R.P., Chaudhary N. et al. Breathe, part of the European Respiratory Society (ERS) (2019) CC2

The article "Under- and over-diagnosis of COPD: a global perspective" reviews the worldwide variation in the prevalence of chronic obstructive pulmonary disease (COPD) and issues related to its misdiagnosis. It highlights that COPD is under-diagnosed due to factors such as limited access to spiromet... more

Download (29)

View PDF (19)

The many faces of diabetes. Is there a need for re-classification? A narrative review

Sakran, N.; Graham, Yiitka.; Pintar, T.; et al. BMC Endocrine Disorders Volume 22 Article Number 9 (2022) CC

The alarming rise in the worldwide prevalence of obesity and associated type 2 diabetes mellitus (T2DM) have reached epidemic portions. Diabetes in its many forms and T2DM have different physiological backgrounds and are difficult to classify. Bariatric surgery (BS) is considered the most effective ... more

Download (103)

View PDF (1378)

Cancer in sub-Saharan Africa
recommended

Ngwa, W.; et al. Lancet Oncology Commission (2022) C2

Lancet Oncol 2022; 23: e251–312Published OnlineMay 9, 2022 https://doi.org/10.1016/S1470-2045(21)00720-8 In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions, data estimates show a major increase in cancer mo... more

Download (127)

View PDF (144)

Tuberculosis in the Americas. Regional Report 2020

Pan American Health Organisation PAHO (2021) C_WHO

This regional report on the situation of tuberculosis (TB) in the Americas contains information from 2019, provided by the countries of the Region through the World Health Organization TB data collection system. These data have been consolidated and analyzed at the regional level. In addition to pre... more

Download (117)

View PDF (124)

Checklist and reference list for developing and reviewing a national strategic plan for HIV

UNAIDS (2020) C_WHO

The checklist and reference list has two parts: high-level cross-cutting content (Part A) and specific programme content (Part B). Part A applies to all countries and contains situation and response analysis, the NSP development process, the goal, targets and priority-setting of the NSP and the prin... more

Download (19)

View PDF (18)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Iheanacho, I.; Zhang, S.; King, D.; et al. International Journal of Chronic Obstructive Pulmonary Disease (2022) CC2

The article "Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review" examines the financial impact associated with moderate-to-very severe COPD. The review analyzes studies published between 2006 and 2016 that discuss healthcare resource utilization (HRU), di... more

Download (22)

View PDF (21)

Global strategy for prevention, diagnosis and management of COPD: 2023 Report

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2023) CC2

The GOLD 2023 report provides a comprehensive update on the global strategy for diagnosing, managing, and preventing chronic obstructive pulmonary disease (COPD). It emphasizes that COPD is a leading cause of death worldwide, driven by risk factors such as tobacco smoking, air pollution, and genetic... more

Download (29)

View PDF (24)

The natural history of chronic obstructive pulmonary disease

Mannino, D.M.; Watt, G.; Hole, D.; et al. European Respiratory Journal (ERJ) (2006) CC2

The article from the European Respiratory Journal discusses the natural history of chronic obstructive pulmonary disease (COPD), emphasizing its increasing global impact on morbidity and mortality. It highlights that while cigarette smoking is a primary risk factor, other influences such as environm... more

Download (25)

View PDF (26)

Management of chronic obstructive pulmonary disease—A position statement of the South African Thoracic Society: 2019 update

Abdool-Gaffar, M. S.; Calligaro, G.; Wong, M.L. et al. Journal of Thoracic Disease (2019) CC2

The document outlines the 2019 update to the South African guideline for managing chronic obstructive pulmonary disease (COPD). It emphasizes the importance of early diagnosis, prevention through smoking cessation, use of bronchodilators as primary pharmacotherapy, and a comprehensive approach to pa... more

Download (43)

View PDF (42)

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f... more

Download (49)

View PDF (20)

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2024

American Diabetes Association Professional Practice Committee Volume 47, Issue Supplement_1 January 2024 (2024) CC2

Ensure treatment decisions are timely, rely on evidence-based guidelines, capture key elements within the social determinants of health, and are made collaboratively with people with diabetes and care partners based on individual preferences, prognoses, comorbidities, and informed ﬁnancial conside... more

Download (260)

View PDF (355)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Cancer in sub-Saharan Africa recommended

Cancer in sub-Saharan Africa
recommended